INSM - インスメッド (Insmed Inc.) インスメッド

 INSMのチャート


 INSMの企業情報

symbol INSM
会社名 Insmed Inc (インスメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インスメッド(Insmed Incorporated)は希少疾患セグメント患者の治療法の開発・商品化を通じて運営するバイオ医薬品会社である。リード製品候補は、マイコバクテリウム・アビウム複合体(MAC)によって引き起こされる治療不応性非結核性マイコバクテリア(NTM)肺疾患の成人患者のための後期段階にある吸入用LAI(ARIKAYCE)、または吸入用リポソームアミカシンである。その初期段階のパイプラインには、メチシリン耐性黄色ブドウ球菌およびNTMを含む、満たされていない医療ニーズの複数のまれな疾患で同社が評価している前臨床化合物が含まれる。初期の臨床段階のパイプラインにはINS1007とINS1009が含まれる。INS1007は、ジペプチジルペプチダーゼ1の経口可逆阻害剤である。INS1009は、肺動脈性高血圧症を含む稀な肺疾患のための差別化された製品プロファイルを提供し得るトレプロスチニルプロドラッグの吸入ナノ粒子製剤である。同社はINS1009の第I相試験を完了した。   インスメッドは、米国のバイオ医薬品メ―カ―。肺疾患の患者向けの吸入治療法を開発し、商品化する。主力製品候補は、肺感染症の吸入抗生物質治療薬「ARIKAYCE(吸入用のリポソ―ム性アミカシン)」である。非結核性抗酸菌症(NTM)による肺感染患者による第2相試験と、緑膿菌の肺感染を伴う嚢胞性線維症(CF)患者による第3相臨床試験を完了した。   Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
本社所在地 10 Finderne Avenue Building 10 Bridgewater NJ 08807 USA
代表者氏名 William H. Lewis ウィリアムH.ルイス
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 908-977-9900
設立年月日 36465
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 214人
url www.insmed.com
nasdaq_url https://www.nasdaq.com/symbol/insm
adr_tso
EBITDA EBITDA(百万ドル) -241.92400
終値(lastsale) 16.93
時価総額(marketcap) 1304301725.94
時価総額 時価総額(百万ドル) 1264.24
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 937.06700
当期純利益 当期純利益(百万ドル) -255.52400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Insmed Incorporated revenues was not reported. Net loss increased 77% to $145M. Higher net loss reflects General and Administrative - other increase from $59K to $62.1M (expense) Research and development -other increase of 83% to $61.2M (expense) Interest expense increase from $3M to $12.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.32 to -$1.89.

 INSMのテクニカル分析


 INSMのニュース

   Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 11:30:00 PR Newswire
BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a…
   Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020  2020/07/27 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2020 financial results on…
   European advisory group backs Insmed's Arikayce (NASDAQ:INSM)  2020/07/24 11:46:25 Seeking Alpha
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Insmed's (NASDAQ:INSM) Arikayce Liposomal 590 m
   Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options  2020/07/24 11:36:00 PR Newswire
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare…
   New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease  2020/07/07 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE® (amikacin liposome inhalation suspension) has been included…
   Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 11:30:00 PR Newswire
BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a…
   Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020  2020/07/27 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2020 financial results on…
   European advisory group backs Insmed's Arikayce (NASDAQ:INSM)  2020/07/24 11:46:25 Seeking Alpha
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Insmed's (NASDAQ:INSM) Arikayce Liposomal 590 m
   Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options  2020/07/24 11:36:00 PR Newswire
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare…
   New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease  2020/07/07 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE® (amikacin liposome inhalation suspension) has been included…
   Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020  2020/07/27 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2020 financial results on…
   European advisory group backs Insmed's Arikayce (NASDAQ:INSM)  2020/07/24 11:46:25 Seeking Alpha
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Insmed's (NASDAQ:INSM) Arikayce Liposomal 590 m
   Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options  2020/07/24 11:36:00 PR Newswire
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare…
   New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease  2020/07/07 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE® (amikacin liposome inhalation suspension) has been included…
   Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  2020/07/06 12:00:00 PR Newswire
BRIDGEWATER, N.J., July 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インスメッド INSM Insmed Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)